Company intelligence / Profile preview

Vega&Santos

South San Francisco, California, United Statescaselaw.findlaw.com ↗

Ownership: Private
Development stage: Other

Overview

Vega Therapeutics has advanced its lead monoclonal antibody candidate, VGA039, into Phase 1 clinical trials targeting von Willebrand disease. Preclinical data suggest VGA039 may serve as a universal hemostatic therapy by modulating Protein S activity to restore thrombin generation and improve clot formation in bleeding disorders.

Therapeutic areas: Hematology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Vega&Santos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vega&Santos.

Explore the full profile